$ALGS

Aligos Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major

PRICE

$1.16 ▲3.509%

Last Close

VOLUME

31,242

DAY RANGE

1.1 - 1.19

52 WEEK

0.8401 - 2.41

Key Metrics

Market Cap

47.02 M

Beta

0.90

Avg. Volume

437.30 K

Shares Outstanding

39.85 M

Yield

0%

Public Float

0

Next Earnings Date

2023-08-03

Next Dividend Date

Company Information

aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-㟠agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.

Website:

HQ: ,

Related News